Acadian Asset Management LLC Increases Holdings in Zoetis Inc. $ZTS

Key Points

• Acadian Asset Management LLC has increased its holdings in Zoetis Inc. by 12.8%, owning 110,407 shares worth approximately $18.17 million.
• Several large investors, including Portside Wealth Group LLC and Tandem Investment Advisors Inc., also significantly increased their stakes in Zoetis during the first quarter of the year.
• Analysts have varied opinions on Zoetis, with ratings ranging from "buy" to "hold," and a consensus target price of $200.88 based on several recent evaluations.

Acadian Asset Management LLC increased its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 12.8% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 110,407 shares of the company's stock after acquiring an additional 12,542 shares during the quarter. Acadian Asset Management LLC's holdings in Zoetis were worth $18,174,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Portside Wealth Group LLC increased its holdings in Zoetis by 24.7% in the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after acquiring an additional 6,672 shares during the last quarter. Tandem Investment Advisors Inc. increased its holdings in Zoetis by 100.3% in the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock worth $65,140,000 after acquiring an additional 198,089 shares during the last quarter. Flagship Harbor Advisors LLC increased its holdings in Zoetis by 31.2% in the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock worth $1,217,000 after acquiring an additional 1,760 shares during the last quarter. Horizon Financial Services LLC purchased a new stake in Zoetis in the 1st quarter worth about $380,000. Finally, Sage Rhino Capital LLC increased its holdings in Zoetis by 117.6% in the 1st quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock worth $1,155,000 after acquiring an additional 3,791 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ZTS shares. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Argus restated a "buy" rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and cut their target price for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Piper Sandler raised their target price on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Zoetis presently has an average rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Stock Performance

Shares of ZTS opened at $150.66 on Friday. The company has a market cap of $66.77 billion, a PE ratio of 25.93, a price-to-earnings-growth ratio of 2.40 and a beta of 0.89. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a 50-day moving average price of $152.53 and a 200-day moving average price of $157.45. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company's revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter last year, the company posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.